ArticleFrontiers in pediatrics2017
Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus.
Article in Frontiers in pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- External Validation of the PLASE Score Prediction Model for PDA Surgery.Pediatric cardiology · 2026Article
- AI, machine learning, and adjudication of hemodynamically significant PDA in extremely premature infants.Pediatric research · 2026Article
- Clinical Impact of the PDA and Its Management on Outcomes of Preterm Infants with NEC: A Review.American journal of perinatology · 2026Review
- Artificial intelligence for patent ductus arteriosus-a systematic review.Frontiers in pediatrics · 2026Review
- Does early-targeted risk-based management of a patent ductus arteriosus improve outcomes in preterm infants? Insights from an observational study.BMJ paediatrics open · 2025Observational
- Machine learning-based prediction of hemodynamically significant patent ductus arteriosus in preterm neonates: a pioneering insight.Frontiers in pediatrics · 2025Article
- Impact of Early Surfactant Administration on Ductus Arteriosus Assessed at 24 h in Preterm Neonates Less than 32 Weeks of Gestational Age.Biomedicines · 2024Article
- Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants.Journal of cardiovascular development and disease · 2023Review
- An Update on Patent Ductus Arteriosus and What is Coming Next.Turkish archives of pediatrics · 2022Article
- Discriminant Analysis of Main Prognostic Factors Associated with Hemodynamically Significant PDA: Apgar Score, Silverman-Anderson Score, and NT-Pro-BNP Level.Journal of clinical medicine · 2021Article
- Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study.Italian journal of pediatrics · 2021Article
- SIMPLE: A Novel Scoring System for Predicting Hemodynamically Significant Patent Ductus Arteriosus Without Echocardiographic Evaluation in Extremely Low Birth Weight Infants.Frontiers in pediatrics · 2021Article
- Echocardiographic predictors of acute kidney injury in neonates with a patent ductus arteriosus.Journal of perinatology : official journal of the California Perinatal Association · 2020Article
- Echocardiography-Guided Management of Preterms With Patent Ductus Arteriosus Influences the Outcome: A Cohort Study.Frontiers in pediatrics · 2020Article
- Growth of extremely low birth weight infants at a tertiary hospital in a middle-income country.BMC pediatrics · 2019Article
- Echocardiographic Prediction of Left Ventricular Dysfunction After Transcatheter Patent Ductus Arteriosus Closure in Children.Frontiers in pediatrics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no consensus about the hemodynamic significance and, therefore, the need to treat a persistent ductus arteriosus in preterm newborns. Since the diagnosis of a hemodynamically significant persistent ductus arteriosus (hsPDA) is made by a summary of non-uniform echo-criteria in combination with the clinical deterioration of the preterm neonate, standardized clinical and ultrasound scoring systems are needed. The objective of this study was the development of a clinical score for the detection and follow-up of hsPDA. In this observational cohort study of 154 preterm neonates (mean gestational age 28.1 weeks), clinical signs for the development of hsPDA were recorded in a standardized score and compared to echocardiography. Analyzing the significance of single score parameters compared to the diagnosis by echocardiography, we developed a short clinical score (calculated sensitivity 84% and specificity 80%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.